L-alanyl-L-glutamine dipeptide — Competitive Intelligence Brief

L-alanyl-L-glutamine dipeptide (L-alanyl-L-glutamine dipeptide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amino acid supplement / Nutritional agent. Area: Critical Care / Intensive Care Medicine.

phase 3 Amino acid supplement / Nutritional agent Critical Care / Intensive Care Medicine Small molecule

Target snapshot

L-alanyl-L-glutamine dipeptide (L-alanyl-L-glutamine dipeptide) — National Cardiovascular Center Harapan Kita Hospital Indonesia. L-alanyl-L-glutamine dipeptide provides amino acid supplementation to support protein synthesis, immune function, and cellular metabolism, particularly in critically ill or post-operative patients.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L-alanyl-L-glutamine dipeptide TARGET	L-alanyl-L-glutamine dipeptide	National Cardiovascular Center Harapan Kita Hospital Indonesia	phase 3	Amino acid supplement / Nutritional agent
Keto Acid	Keto Acid	Peking University First Hospital	marketed	Amino acid supplement / Nutritional agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amino acid supplement / Nutritional agent class)

1. National Cardiovascular Center Harapan Kita Hospital Indonesia · 1 drug in this class
2. Peking University First Hospital · 1 drug in this class